Armor Investment Advisors LLC Decreases Stake in Johnson & Johnson $JNJ

Armor Investment Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 12.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,310 shares of the company’s stock after selling 338 shares during the period. Armor Investment Advisors LLC’s holdings in Johnson & Johnson were worth $353,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter worth approximately $48,000. Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter valued at $52,000. Finally, Pandora Wealth Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Loop Capital set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 22nd. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, Stifel Nicolaus raised their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $201.05.

Johnson & Johnson Stock Performance

JNJ opened at $206.07 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $206.94. The firm has a market capitalization of $496.48 billion, a PE ratio of 19.89, a PEG ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average price is $188.83 and its 200 day moving average price is $172.13.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.